Skip to main content

Specialty Pharmacy

  • Key approvals see big sales in first months

    Among the 22 novel new drugs approved by the Food and Drug Administration in 2016, about half were considered specialty drugs, and Diplomat identified four key specialty approvals that innovate in certain categories. Two of these were in the hepatitis C space, which has driven specialty growth for several years.

    (To view the full Category Review, click here.)

  • Fred's February sales decline, but company pleased with progress

    MEMPHIS, Tenn. — Fred’s Pharmacy reported total sales for its fiscal month of February, which ended Feb. 25, decreased 3.5% on a year-over-year basis to $165.4 million. Total comparable store sales declined 4%, compared with an 0.8% increase during the same time period in 2016.

    Fred’s CEO Michael K. Bloom stressed the company is pleased with progress it is making under its strategic plan though.

  • CVS selects electronic health record system for specialty care

    WOONSOCKET, R.I. — CVS Health on Thursday selected Epic as the electronic health record system for CVS Specialty’s care management programs.

    According to CVS, the transition to Epic will help integrate and improve clinical processes for CVS Specialty, including Accordant, which provides care management program services for patients with rare, chronic diseases. This announcement expands the Company's use of the Epic EHR system beyond MinuteClinic which transitioned to the system in 2015.

  • Walgreens designates more than 50 specialty pharmacies as cancer-specialized centers

    DEERFIELD, Ill. — Walgreens on Wednesday designated more than 50 of its local specialty pharmacies as cancer-specialized locations. Each of the locations will be led by pharmacists and pharmacy technicians who have advanced cancer training and expertise and are committed to making sure patients get the medications and answers they need.

  • PhRMA names new leads on state advocacy, strategic alliances

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America has announced leadership changes to some of its advocacy efforts as longtime SVP advocacy Jeff Bond is set to retire. The organization named SVP Scott LaGanga as head of PhRMA state advocacy, assuming Bond’s responsibilities. Shannon Graham has been named SVP and will lead PhRMA’s advocacy and strategic alliances program. 
     

  • Diplomat acquires Houston-based Affinity Biotech

    FLINT, Mich. — Diplomat Pharmacy on Wednesday announced that it had completed an acquisition of Affinity Biotech, a specialty pharmacy and infusion services company based in Houston, Texas, providing treatments and nursing services for patients with hemophilia. 
     
    Diplomat acquired the company for $16 million in cash and up to an additional $4 million in contingent payments. 
     

  • Fred’s Pharmacy sees progress in specialty pharmacy sales

    MEMPHIS, Tenn. — Fred’s Pharmacy saw total sales for the month of January decline 5.6% year over to $148.1 million from $156.9 million. Comparable-store sales for the month decreased by 4.8% versus an increase of 0.7% during the prior year period.

    As for its 2016 fourth quarter, total sales for the fourth quarter of 2016 decreased 4.3% year over year to $530.7 million from $554.6 million in the fourth quarter of 2015. On a comparable-store basis, Q4 sales decreased 3.6% versus an increase of 1.7% in the year-earlier period.

  • PhRMA elects new board members, adds member company

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday officially elected new board members and welcomed its latest member company, UBC. 
     
X
This ad will auto-close in 10 seconds